Company information
- Ticker
- BIOE
- Country
- United States
- Sector
- Health Care
- Industry
- Pharma
Bio Essence Business Summary
Bio Essence Corp (BIOE) is a wellness-focused biotechnology company that generates revenue through a dual-model approach consisting of direct-to-consumer product sales and business-to-business manufacturing services. The company’s primary business segments include the development and distribution of traditional Chinese medicines (TCM), herbal supplements, and functional drinks, alongside a robust Original Equipment Manufacturing (OEM) and private label division that services third-party health brands. As of early 2026, the company is aggressively expanding into a third segment: an AI-enabled digital health platform designed to integrate telemedicine, personalized nutrition, and diagnostic tools into its holistic ecosystem. Bio Essence operates within a highly fragmented nutraceutical market, competing directly with established players such as Ortho Molecular Products, Paragon Laboratories, and Nutrascience Labs. The company distinguishes itself by leveraging its recent 2026 upgrade to the OTCQB Venture Market to enhance liquidity and fund its transition from a traditional supplement manufacturer to a tech-integrated holistic health provider. Leadership is spearheaded by Chairperson and CEO Yin Yan, a registered lawyer with a J.D. and an M.B.A. in Technology Management from the University of New South Wales, who brings over 20 years of experience in international trade and corporate management. She is supported by Chief Operating Officer Tuan Tran, an operations veteran with over two decades of expertise in FDA regulatory compliance and Lean Manufacturing, and Chief Financial Officer William A. Sluss, a dual-qualified CPA and attorney who oversees the firm’s financial strategy and regulatory reporting. The company’s strategic direction is further influenced by major shareholder Jian Yang, who has maintained a controlling interest since 2016. This executive team is currently focused on a $5 million Regulation A offering to scale their AI-driven health initiatives and expand their network of over 100,000 healthcare practitioners worldwide.